Celcuity launches $150M convertible notes + $75M common stock offerings; also to draw $30M loan

Celcuity Inc.

Concurrent underwritten offerings: $150M convertible notes due 2031 and $75M common stock; 30-day over-allotment options for additional $22.5M notes and $11.25M stock.
Proceeds to fund capped call transactions (reduce dilution on note conversion) and for working capital, clinical trials, R&D.
Intends to draw $30M Term D Loan in late August 2025 after achieving clinical milestone under existing loan agreement.
Amended loan with Innovatus/Oxford: $25k fee, extended conversion right on Term A loan to $10/share through May 9, 2026.
Preliminary cash at June 30, 2025: ~$168.4M (down from $283.1M a year ago).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.